The delayed appearance of motor symptoms in PD poses a crucial challenge for early detection of the disease. We measured the binding potential of the selective dopamine active transporter (DAT) radiotracer [
Introduction
Parkinson's disease (PD) is a neurodegenerative pathology characterized by the progressive death of the dopamine (DA) neurons of the substantia nigra pars compacta (SNpc) that innervate the caudate nucleus and putamen. Chronic treatment with MPTP, a specific toxin of DA cells, produces symptoms similar to those observed in PD patients and provides a useful model of PD.
In both human and NHP DA cell loss has to exceed 30% and the DA markers in the caudate/putamen to drop by 60-70% before PD motor symptoms are observed (Agid, 1991; Burke and O'Malley, 2013; Tabbal et al., 2012) , suggesting the existence of compensatory and adaptive processes. An improved understanding of this premotor PD period will contribute to clinical advances in the diagnosis, and treatment of PD.
In non-human primates, the chronic low dose MPTP-treatment causes a tempo of DA cell loss and a repertoire of motor symptoms similar to those observed in PD (Bezard et al., 1997a (Bezard et al., , 1997b Schneider and Pope-Coleman, 1995) , thereby providing a valuable model for the investigation of the phase preceding the appearance of characteristic motor symptoms. Interruption of MPTP intoxication produces a stabilization of motor symptoms and in some cases, is followed by spontaneous motor recovery (Boulet et al., 2008; Petzinger et al., 2006; Vezoli et al., 2011) . In humans, even a short lasting exposure to MPTP can cause a progressive and ultimately fatal pathology in the SN (Vingerhoets et al., 1994) . The progression of clinical symptoms correlates well with levels of nigrostriatal DA depletion in both PD patients (Burke and O'Malley, 2013; Hornykiewicz, 2006 Hornykiewicz, , 2008 and MPTP-treated NHP (Blesa et al., 2010) . However, DA lesion can be severe in motorrecovered animals following exposure to MPTP (Boulet et al., 2008) as well as in motor-asymptomatic animals (Bezard et al., 2001; Schneider, 1990) ; suggesting that the compensatory process is not uniquely DA dependent (Bezard et al., 2003; Mounayar et al., 2007) . Hence, understanding the evolution of DA metabolic alterations during the premotor phase of the pathology will give an improved insight into the compensatory process (Tang et al., 2010) . Given the absence of a reliable marker of the premotor PD phase in humans, investigation of animal models remains crucial (Berg et al., 2013; Siderowf and Lang, 2012) .
In view of the above we have studied the DA status of the nigrostriatal pathway in-vivo using Positron Emission Tomography (PET), a method of choice to quantify in-vivo neurodegeneration in longitudinal studies (Brown et al., 2013; Masilamoni et al., 2010) . We used the cocaine analog [ 11 C]PE2I labeled with carbon 11, a ligand displaying a selective affinity for the DA transporter (DAT) thereby allowing precise measurement of its density (Poyot et al., 2001) . Imaging studies in both PD patients and MPTP-monkeys show a drop in DAT markers in SN and striatum that correlates with the severity of disease (Brown et al., 2013; Kugaya et al., 2000) , and with DA neuron loss in SN and nigrostriatal depletion (Brown et al., 2013; Niznik et al., 1991) . Additionally, DAT label in de novo patients has been shown to predict long-term motor and non-motor outcomes (Ravina et al., 2012) . However few studies if any have directly addressed the premotor PD state in humans.
In order to analyze the functional link between the onset of clinical motor and non-motor symptoms (here cognitive) and levels of nigrostriatal DA cell damage, we carried out longitudinal PET analysis of the [ 11 C]PE2I non-displaceable binding potentials ([ 11 C]PE2I-BP ND ) in monkeys submitted to low-dose MPTP-treatment. Clinical symptoms were assessed by extensive daily clinical scoring and task performance was evaluated using a behavioral test relying on the integrity and DA innervation of the fronto-striatal axis (Decamp and Schneider, 2004; Schneider and Kovelowski, 1990) .
Methods

Ethical statement
All procedures were carried out according to the 1986 European Community Council Directives (86/609/EEC) which was the official directive at the time of experiments, the French Commission for animal experimentation, the Department of Veterinary Services (DDSV Lyon, France). Authorization for the present study was delivered by the "Préfet de la Région Rhône Alpes" and the "Directeur départemental de la protection des populations" under Permit Number: #A690290402. All procedures were designed with reference to the recommendations of the Weatherall report, "The use of non-human primates in research". All monkeys were closely monitored on a regular basis throughout the day, by researchers and animal care staff, in order to ensure that levels of health and welfare were strictly maintained, particularly during the MPTP period. Adaptations to housing and feeding procedures were made in direct response to individual symptoms in the MPTP phase, for example adaptations of water provision to ensure monkeys were able to drink ad libitum. To alleviate physical suffering from motor symptoms progression (such as rigidity) the intoxication procedure was first cautiously stopped when the PMRS-motor score was above ten for two consecutive days following one MPTP injection; further, antalgic and/or antiinflammatory drugs were delivered to animals suffering from advanced motor symptoms progression. Before being sacrificed, animals were first tranquilized with a preanesthetic agent (chlorpromazine hydrochloride, Largactil) and anesthesia was induced with Ketamine before deep anesthesia was obtained by means of a large dose of pentobarbital sodium (Vibrac, 100 mg kg − 1, i.p.; lethal dose confirmed by complete loss of corneal reflex).
Animals and MPTP intoxication
Four late middle-aged (11-13 years old) female macaque monkeys (Macaca fascicularis [4-5 kg weight]) were intoxicated with low-dose MPTP injections (0.2 mg kg − 1, i.m). Animals were housed in a room dedicated to MPTP experiments, with free access to water and received food twice a day. The neurotoxin was delivered according to two different regimes: 1) chronically each 3-4 days and 2) acute intoxication (daily injections) as described previously (Mounayar et al., 2007; Vezoli et al., 2011) . In cases 1 and 3, the first session of MPTP injections was suspended as soon as the clinical score reached symptomatic threshold ( Fig. 1 and Supplementary Table 1) , allowing investigation of DA neurotransmission after spontaneous behavioral recovery (Vezoli et al., 2011) . For the last-MPTP intoxication which led to persistent motorsymptoms in all cases, injections were cautiously stopped when the PMRS-motor score was above ten for two consecutive days following a single MPTP injection. For result presentation, animals were grouped according to their clinical state at the time of PET-scan (see Fig. 1 and Supplementary Tables 2-4) i.e. 1-premotor (n = 4, cases 1-4); 2-spontaneously recovered (n = 2, cases 1 and 3); and 3-stable symptomatic (n = 4, cases 1-4). Data are presented according to the corresponding periods of the MPTP-intoxication protocol: 1-early_MPTP (second week of MPTP intoxication, premotor i.e. motor-asymptomatic, within the pre-symptomatic period when clinical motor score below 5); 2-post-MPTP Recovery (following arrest of first MPTP injections, clinical motor score returned below 5 throughout this period i.e. nonsymptomatic); and 3-post-MPTP Symptomatic (following arrest of last MPTP injections, clinical motor score remained stably above 5 during this period i.e. motor-symptomatic). Case 4 had a high-score two weeks post-MPTP (motor symptoms N15), characterized by severe rigidity. Musculoskeletal pain is a recognized source of pain syndromes and discomfort in Parkinson's disease patients. We thus delivered regularly ketoprofen (Profenid), from week 5 post-MPTP, in order to relieve suspected musculoskeletal pain. Subsequently the clinical score for this animal progressively improved, due to amelioration on the rigidity scale and ability to manipulate food (from week 5 to week 10 post-MPTP, Fig. 1B ), but stabilized at week 10 and remained largely symptomatic (score N12) despite continuous treatment and disappearance of apparent musculoskeletal pain syndrome. No analgesics or anti-inflammatory drugs were delivered to premotor or recovered animals.
Clinical motor evaluation
Clinical scoring was done by three experimenters at separate times throughout the day, 3-5 days per week using the Parkinsonian Monkey Rating Scale (Vezoli et al., 2011) . The PMRS contains a motor component, employing a previously published scale (Benazzouz et al., 1995) used to define the onset of the motor symptomatic period. The total score for freezing (0-3), resting tremor (0-3, for right and left side), rigidity (0-3), posture (0-2), bradykinesia (0-3), and ability to manipulate food (0-3, for right and left side) was used to frame injections (maximum total score of 23): a score below 5 defined the nonsymptomatic state in premotor and recovery periods, and a score above 5 defined symptomatic periods.
Cognitive behavioral task
Cognitive performance was monitored 3-5 days a week using a previously described behavioral test (Vezoli et al., 2011) . Briefly, performance on the 'detour task' was evaluated by the percent of successes (retrieval of reward on the first reach, over the total number of trials) and errors (barrier hits, over the total number of responses observed-there could be several responses per trial except in the case of success). Errors due to motor impairments were classified as such and further discarded from the performance evaluation, so as to avoid confounds due to the symptomatic state of the animal. The performance on the 'detour task' depends on the integrity of frontal cortex, the dopaminergic system and DA innervation of frontal cortex (Diamond, 1996) and has been used to assess the impact of lesion of the nigrostriatal axis on cognitive performance as well as potential therapy for cognitive impairments (Schneider et al., 1998; Taylor et al., 1990a Taylor et al., , 1990b . C]PE2I specifically binds with high affinity and selectivity to DAT (Ki = 17 nM) and is considered to provide an index of the integrity of the DA pathway that has been used for PD diagnosis (Emond et al., 1997; Poyot et al., 2001; Shih et al., 2006 for a review). [ 11 C]PE2I PET studies were performed with an ECAT Exact HR + tomograph (Siemens CTI), in 3D acquisition mode, covering an axial distance of 15.2 cm. The transaxial resolution of the reconstructed images was about 4.1 mm full-width and half maximum in the center. Transmission scans were acquired with three rotating 68 Ge sources and were used to correct the emission scans for the attenuation of 511 keV photonrays through tissue and head support. C]PE2I (as determined by HPLC) was above 98% (Poyot et al., 2001) .
PET examination
Anesthesia of the monkeys was induced with 15 mg/kg Zoletil (Tiletamine and Zolazepam, Virbac, Carros, France) 30 min after premedication with 0.1 mg/kg atropine sulfate. A MRI-compatible stereotaxic frame (Kopf, CA, USA) was used to secure the head during the PET scan and reduce variability in the measure. A cannula was inserted in the femoral vein. [ 11 C]PE2I (74 to 111 MBq) was injected as a bolus over a 4 s period followed by a saline flush. Radioactivity was measured in a series of 24 sequential time frames of increasing duration (from 30 sec to 10 min; total time 70 min). A. Four animals were used in the study and grouped according to their clinical state in control (n = 4, cases 1-4); premotor (n = 4, cases 1-4); spontaneously recovered (n = 2, cases 1 and 3); stable symptomatic (n = 4, cases 1-4). Cases that recovered following MPTP-injections offset entered a second MPTP phase in order to induce a stable parkinsonian state. B. Longitudinal evolution of the clinical score (in weeks) through the protocol for all cases; score has been aligned to the last MPTP-injection. PET-scan week sessions are depicted in blue. Clinical score for cases 2 and 4 are plotted twice; the first MPTP intoxication (in dashed lines) was also the last MPTP and used in the premotor group. Red arrowheads indicate the beginning of MPTP intoxication for each case.
PET modeling
Based on anatomical-MRI and maximum probability atlas (Ballanger et al., 2013) , 88 ROIs were defined and used to follow binding potential on PET-scans for these regions throughout the protocol; here we focused on striatal structures (10 ROIs-(see Supplementary Fig. 1 ), anterior-posterior caudate nucleus and putamen and the ventral striatum). We additionally document changes in DAT binding for the cortical regions showing substantial amount of binding (cingulate cortex) and through the three main periods: premotor, motor-recovered, and motor-symptomatic. Anatomical MRI acquisition was performed in a different session and consisted of a 3D anatomical T1-weighted sequence using a 1.5-T Siemens Magnetom scanner (Siemens AG, Erlangen, Germany). The anatomical volume covered the whole brain with 0.6 mm cubic voxels. Each PET scan was summed over frames, before being registered between PET acquisitions to provide a mean PET image. The mean PET images were manually pre-registered to the anatomical individual MRI based on anatomical landmarks (anterior commissure, left and right orbital center, left and right caudate head, left and right posterior ventral putamen using the graphic application register-MINC-toolbox) in order to compute a rigid transformation that was then used as a starting point for positioning the MRI and PET images before the following automated procedure. Individual MRI scans were then registered to our Fascicularis MRI template (Ballanger et al., 2013) . Transformations from native PET to individual MRI and individual MRI to template were concatenated in order to provide direct (and inverse) affine transformations from PET native spaces to the template space. With these transformations, see (Ballanger et al., 2013) for a description of procedures, the brain fascicularis maximum probability atlas was then propagated to PET native spaces so as to allow extraction of regional PET time activity curves (TACs) of the 88 ROIs. Quantification of regional [
11 C]PE2I non-displaceable binding potentials (BP ND ) was performed using the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) . Time activity curves of the cerebellum (excluding the vermis) were used as the reference for the SRTM (Seki et al., 2010) . SRTM modeling provided three macro-parameters: BP ND , k2 (rate constant for transfer from the tissue to the plasma compartment) and R1 (ratio of the K1 rate constants of the target region and the reference region, K1 being the transfer rate from the plasma to the tissue compartment). Parametric images of BP ND were computed at the voxel level with right and left averaged cerebellum TACs as reference region. Because the registration procedure is semi-automated, we repeated the procedure three times for each case in order to account for within-measure variance (for each case, 2 ROIs per hemisphere were used for caudate and putamen and one for the ventral striatum). In case 1, for the premotor scan, curves of Bq/cc fixation over scantime produced profiles for ROIs that did not attain a plateau and showed slight increases over successive frames of this session. Thus, it could be assumed that the equilibrium between the free and unspecific binding compartments was not reached (Costes et al., 2007) . Another possible explanation is that the ROI TAC has averaged voxel TACs with different patterns such that SRTM could not evaluate BP ND values at the ROI level. Alternatively, BP ND were also computed at a voxel level. Voxel TACs were submitted to the SRTM modeling with the cerebellum as reference region, providing parametric image of BP ND .
Identical quantification procedures for control and premotor scans were used for both group and individual comparisons. Maximum and averaged values of voxel BP ND per ROI (caudate, putamen and ventral striatum for left and right hemisphere) were extracted and used to compute relative binding difference between scans in the same subject. Because maximum voxel-level BP ND per ROI could be potentially fraught with noise, we compared them to mean voxel-level BP ND per ROI (Supplementary Fig. 2 ). This shows that: i) maximum and mean voxel-level BP ND per ROI are highly correlated with ROI-level BP ND but maximum voxel-level BP ND is closer to ROI-level BP ND , ii) maximum and mean voxel-level BP ND assume identical statistical test result concerning increased DAT-binding in the early_MPTP effect (+ 22.7 ± 5.6% and +18.6 ± 2.9%, relative change compared to control for maximum and mean voxel-level BP ND respectively) and iii) maximum and mean voxel-level BP ND are highly correlated (R = 0.95, p = 4.7E − 6 ). Note that our conclusions on the early_MPTP results are based on the averaged voxel-level BP ND . Maximum voxel-level BP ND was extracted here only to show the correspondence with ROI-level BP ND . Parametric BP ND images of the early_MPTP period were spatially normalized to stereotaxic space in order to perform voxel-by-voxel statistical analysis with SPM8 (Welcome Trust Centre for Neuroimaging, London, UK) presented in Fig. 3D . Case 4 could not be included in the premotor group because its PET-images were qualitatively altered due to the incidental presence of the infusion line in the field of view of the PET camera, thereby excluding further statistics with other scans.
Regional assignment of PET changes
In order to visualize the maps of [ 11 C]PE2I-BP ND changes subsequent to MPTP intoxication ( Supplementary Fig. 3 ), we performed subtraction of control from early_MPTP parametric BP ND images (after spatial normalization to template space) for each case before averaging as group data. The observed decrease in DAT binding was more focused than the DAT increase and consistently localized in the posterior part of the atlas-defined left posterior putamen ( Supplementary Fig. 4) ; therefore, the DAT increase (in the anterior part) oversized and masked the DAT decrease (in the most posterior part) at the ROI-level. We used the 2.5th percentile of the overall brain distribution of difference voxellevel values (Supplementary Fig. 5 ) to describe regions of significant decrease in DAT binding (values inferior to −0.39, Fig. 2B) ; whereas the 97.5th percentile was used to describe regions of significant increase in DAT binding (values superior to +0.54, Fig. 2A ). The same method was applied for each individual case in the early_MPTP condition (Supplementary Fig. 5 ) and for the other conditions (post-MPTP recovered and symptomatic) to define statistical threshold in parametric maps of the difference in BP ND between two given conditions.
For each case, a PET was done in the control period (prior to MPTP intoxication) and used to compute the change relative to control for all periods (early_MPTP, post-MPTP recovered and symptomatic). Individual cases data are reported in Supplementary Table 5 for the early_MPTP condition.
Control levels of cortical [ 11 C]PE2I-BP ND were in average 91.2% lower than striatal levels. However, the top 5% of cortical DAT binding was not different from the lowest 5% of striatal DAT binding (ranksum, p N 0.05). We therefore document changes for the top 5% of cortical DAT binding which was located in the limbic cingulate cortex ROI (Ballanger et al., 2013) .
Immuno-histological procedures
Three age and weight matched M. fascicularis, served as controls for the three cases processed (cases 1, 3 and 4). Deep anesthesia was induced with Ketamine after premedication with chlorpromazine hydrochloride (Largactil) followed by a lethal dose of pentobarbital sodium (Vibrac, 100 mg.kg , i.p.; confirmed by complete loss of corneal reflex) before animals were transcardially perfused with saline (0.9% with procaine) and 4% paraformaldéhyde and 0.05%-glutaraldehyde in phosphate buffer. Cryoprotection was ensured by sucrose gradients (10-30%) perfusion post-fixation. Brains were removed, kept in cryoprotecting liquid overnight and coronal 50 μm thick sections cut on a freezing microtome. Sections were processed together with equivalent sections from control animals for Tyrosine Hydroxylase (TH; Millipore, #MAB318) and DAT (Millipore, #MAB369) immunochemistry visualized with 3,3-diaminobenzidine, in Ni 2 + H202 (0.5-1.0%).
All sections were washed, mounted, dried, and dehydrated in increasing gradients of ethanol, cleared in toluene, mounted with mounting medium and cover slipped.
Semi-quantitative immunohistochemistry
Evaluation of the extent and amplitude of the nigrostriatal lesion was obtained with semi-quantitative immunohistochemistry (Dzahini et al., 2010) of the striatal structures. The mean optical density (O.D.) of TH and DAT immunoreactive regions were computed on at least 5 sections per animal (5-20) from 8bit images, normalized and compared with two-sample t-test separately for each ROI (ttest2, Matlab). In Supplementary Figs. 7-8 the composite CTR and MPTP images have been enhanced for brightness and contrast, for illustration purpose.
Statistics
Data were first grouped according to MPTP dosage in order to describe behavioral performance at the very early stages of MPTP intoxication (when no clinical symptoms where observed i.e. clinical score null) (Fig. 3C) . We then separated MPTP and post-MPTP periods into five equal epochs and grouped variables in each. This segmentation method (Vezoli et al., 2011) better reveals normalized stages of disease progression thereby allowing comparison of different parameters across an equivalent number of epochs for all subjects. These epochs are referred as quantiles . Results are presented as means ± standard errors.
Parameters were compared to control values by a treatmentcontrast test using control measures as the first level (estimated standard errors and z-ratio were computed using GLM fit and contrast result was given by two-tailed p-values corresponding to z-ratio based on a Student t-test). Significance was considered at p b 0.05. Statistical Table 2 ) or voxel-level and these different values showed significant correlation ( Supplementary  Fig. 2 ).
Results
Control scans returned comparable BP ND values across animals as estimated at the ROI-level (Supplementary
Alterations of [
11 C]PE2I-BP ND during MPTP-treatment and relation to emerging non-motor cognitive symptoms Surprisingly, the early effect of MPTP, during the so-called premotor period, was characterized by a marked increase of striatal [
11 C]PE2I-BP ND in all cases tested (+18.6 ± 2.9%, percent change from control, mean voxel-level BP ND per ROI). Following control scans, PET images of [ 11 C]PE2I binding to DAT were obtained in 3 animals (cases 1-3) 3-5 days after the first two weeks of MPTP intoxication (total cumulative dose 0.6 mg/kg). In all cases there was a consistent increase of [ 11 C] PE2I-BP ND levels in the striatum (mean voxel-level BP ND , Supplementary Table 5 ). These increases were significant at both group (Figs. 2A, 3B , D) and individual levels ( Supplementary Figs. 3-4) . Group values of voxel-level BP ND per ROI after 3 injections of MPTP show an increase that looks slightly more pronounced in the right putamen (Fig. 3B) . However, SPM analysis (Fig. 3D ) and statistical maps of parametric BP ND images ( Fig. 2A) exhibit a significant DAT increase focused on the left anterior putamen (SPM results with a voxel height threshold of T = 1.66, comparing early_MPTP vs. CTR: k = 18.62 mm 3 ; T = 2.28 and 3.56, P = 0.019 and 0.002 (uncorrected, no extent threshold) for right and left striatum respectively). Importantly, the statistical maps also exhibit a significant decrease of DAT binding in the left posterior putamen (Fig. 2B) . Thus, averaging the lateralized increase and decrease in one atlas ROI obscures the finding of a more pronounced increase in the left anterior putamen. This was even more pronounced when considering anterior and posterior ROIs of caudate and putamen (Supplementary Fig. 6 ). Both group (Fig. 2 .A) and individual ( Supplementary  Fig. 4 ) parametric images of difference in BP ND confirm that the broad striatal [ 11 C]PE2I-BP ND increase is an unambiguous feature of the initial phase of the MPTP-treatment during which the nigrostriatal insult is supposedly modest. The distribution also shows that the decrease of DAT binding is much more restricted. This [ 11 C]PE2I-BP ND decrease in the early_MPTP condition was consistently involving a sub-part of the posterior putamen (Fig. 2B) . The presence of a consistent localized decrease of [ 11 C]PE2I-BP ND in the posterior putamen (sub-part of the left posterior putamen, see Supplementary Fig. 4) suggests that the observed broad increase in the more anterior striatal DAT binding reveals an intrinsic compensatory mechanism of the DA system at the very early stages of the nigrostriatal lesion.
Because we used systemic injections of MPTP, we verified if the lateralization of the early response to MPTP could stem from an already present asymmetry in the control scans. CTR scans showed that left striatum presented overall +1-4% more DAT binding compared to the right striatum but this was not significant considering the whole striatum (signtest, left vs. right: p = 0.1539 for mean voxel-level BP ND ). This inter-hemispheric asymmetry depended only on the putamen for which the left side had + 6.0 ± 3% more DAT binding compared to the right side (percent change for mean voxel-level BP ND ; signtest, left vs. right: p b 10 −4 for mean voxel-level BP ND ).
As expected, cognitive behavior symptoms emerged gradually throughout the course of MPTP intoxication. However, the error rate was significantly altered only in the period following 3 MPTP injections (Fig. 3C )-a period when no motor symptoms were observed (Fig. 3A) . This coincided with the observed increase and decrease of DAT binding in the relatively more cognitive region of the striatum i.e. anterior striatum (Haber, 2003) and in the motor region i.e. posterior putamen, respectively. Because of the lateralization of these changes (Fig. 2) , we further separated trials of the task regarding the position of the opening (Vezoli et al., 2011) . We identified a contralateral effect of these changes in DAT binding on cognitive performance deterioration i.e. performance on the right side of the animal was significantly altered whereas performance for the left side was not (Fig. 3C ). This effect was clear only during the early_MPTP period i.e. following 3 MPTP injections. With . Arrow indicates that PET-scans were made while no motor deficits were observed. B. Boxplots of group value of the difference in voxel-level SRTM estimates of DAT binding between the control (CTR) condition and the second week of MPTP-intoxication (early_MPTP) in the different striatal structures. C. Behavioral performance for the group in control condition, the week following first MPTP-injection (3 MPTP injections in total), the second week when PET-scan was made (blue arrow) and a period when 3 more MPTP-injections were made. D. Structural Probability Map (n = 3) analysis showing regional focus of early MPTP effect on striatum prior to motor symptoms (pre-symptomatic stage). Color scale: T-score. Statistics refer to a contrast test with CTR as the first level, ns: non-significant, *: p b 0.05, **: p b 0.01, ***: p b 0.001. Note the x-axis in A refers to Quantiles (see Methods section for definition).
continuing MPTP injections, the lateralization of performance disappeared i.e. right and left side performances were both significantly altered. Importantly, this cannot be imputed to overt motor deficits from the right body parts as no motor errors were observed in this period. The restricted number of cases tested (n = 3) doesn't allow us to determine whether the [ 11 C]PE2I-BP ND increase or decrease correlated best with deteriorated performance.
There was no significant change in [ 11 C]PE2I-BP ND in the limbic cingulate cortex for the premotor condition (CTR, right: 2.4 ± 0.8 and left: 2.9 ± 0.7 vs. premotor, right: 2.1 ± 1.3 and left: 2.4 ± 1.5 [ 11 C]PE2I-BP ND , arbitrary units). This strengthens the hypothesis that the early compensatory increase in DAT binding is restricted to the striatum. However, we cannot fully exclude changes in the other cortical ROIs with lower levels of DAT binding measured with the current technique.
Alterations of [ 11 C]PE2I-BP ND after MPTP-treatment and relation to induced motor and non-motor cognitive symptoms
In order to verify the expected reduction of DAT binding after prolonged MPTP intoxication, [
11 C]PE2I-BP ND was longitudinally followed subsequent to interruption of MPTP-treatment in two other conditions ( Fig. 1) : spontaneous motor recovery (n = 2, clinical score b 5) and long-term symptomatic parkinsonian state (n = 4, clinical score NN 5). These results are now entirely based on ROI-level BP ND .
Spontaneous motor recovery
In two cases (1 and 3) MPTP injections were suspended as soon as clinical score reached the symptomatic threshold (score N5). The clinical score increased progressively and a transient symptomatic state was observed (Supplementary Table 1), after which clinical score returned to baseline level (Fig. 4A) . Clinical symptoms emerged in the following order: mild bradykinesia, stooped posture, rare freezing and intermittent resting tremor for case 1; mild bradykinesia, stooped posture, intermittent resting tremor and rare freezing for case 3. PETscans were performed i) at the peak of clinical score (two weeks following last MPTP injection), corresponding to a score around 10 and ii) at two intervals following maximum recovery (Fig. 4A-B Table 3 ). The ventral striatum was the most preserved structure (Fig. 4B, Supplementary Table 3) , consistently with previous reports on pattern of nigrostriatal denervation both following chronic MPTP intoxication e.g. (Perez-Otano et al., 1994) and in PD patients (Gibb and Lees, 1991) , but still showing 60.1 ± 14.2% (Fig. 4D ). While clinical score had returned to control levels, cognitive behavior deficits remained in the recovery period (Fig. 4C) . Error rate gradually increased and success rate decreased during the MPTP period reaching a point for which the error rate was above the success rate. After MPTP injections were stopped, this decline in cognitive behavior performance worsened during clinical motor recovery (Quantiles Recovery 1-2 i.e. 5-6 weeks post-MPTP, Fig. 4C ). Once maximum motor recovery was reached, performance tends to improve but still remained significantly deteriorated confirming previous results (Vezoli et al., 2011) . Importantly, while errors due to pure motor symptoms are carefully discounted in the calculation of error rate such that increasing error rate is not linearly related to the degree of motor impairments, we cannot rule out that motor symptoms might have specifically influenced motor planning during the transient symptomatic phase.
In recovered cases, limbic cingulate cortical DAT level was significantly reduced compared to control (CTR, right: 2.1 ± 0.8 and left: 2.7 ± 0.6 vs. 
Stable Parkinsonism
In all cases (n = 4) the MPTP-protocols gave rise to a long-lasting, stable parkinsonian syndrome (Fig. 5A ). For the animals that spontaneously recovered following arrest of the initial MPTP-treatment, a second period of intoxication was pursued in order to obtain a persistent symptomatic state. Clinical symptoms emerged in the following order: stooped posture, mild bradykinesia, rare freezing and intermittent resting tremor for case 1; intermittent resting tremor, mild bradykinesia, mild rigidity, stooped posture and rare freezing for case 2; rare freezing, intermittent resting tremor, stooped posture and bradykinesia worsening for case 3; mild bradykinesia, stooped posture, rare resting tremor and rare freezing for case 4. Scans were performed while monkeys were stably expressing parkinsonian motor symptoms (Quantile Symptomatic 3-5, Fig. 5A-B) i.e. at least more than seven weeks following the last MPTP injection.
[ Interestingly, DAT binding decrease in this structure (percent change from control) was the only one which correlated significantly with clinical score after induction of stable Parkinsonism (R = −0.96,
). This suggests that the relatively spared ventral striatum constitutes the remaining pool of nigrostriatal terminals involved in late compensation. Compared to [
11 C]PE2I-BP ND levels obtained after clinical recovery, the values obtained in the stable symptomatic period (for these two cases) were further decreased by 31.2 ± 4.9% (Fig. 6) . Cognitive performance was dramatically and persistently altered following MPTP-intoxication (Fig. 5C ).
Post-mortem evaluation of the nigrostriatal lesion
Immunohistological precipitations were carried out on sections from three of the four animals treated (cases 1, 3 and 4; Supplementary  Figs . 7-8 and Supplementary Table 6 ). Immunohistochemistry confirmed that MPTP intoxication caused severe deterioration of the nigrostriatal pathway. In the striatum TH and DAT labeling were reduced by about 60% and 70%, respectively (Supplementary Fig. 8 ). TH and DAT depletion was overall quantitatively similar between cases. However, some presented relatively more spared accumbens ( Supplementary Fig. 7 ) and mesencephalum. Importantly, decreased levels of striatal DAT O.D. compared to controls (Supplementary Table 6 ) were consistent with the decrease of DAT as evaluated in-vivo by PET (Supplementary Table 4 ).
Discussion
Our data have revealed an important increase in [ 11 C]PE2I-BP ND during the initial stages of MPTP intoxication. At this stage animals were in the premotor period yet they presented non-motor cognitive symptoms. Below we propose that the increase in striatal DAT-binding we observed during the premotor phase of MPTP-monkeys is a very early adaptive mechanism triggered at the level of remaining DA terminals. Further research on this physiological manifestation might warrant its use as an additional premotor PD marker (Mossa et al., 2012; Ziebell et al., 2012) .
The broad increase of DAT binding in the caudate and anterior putamen was accompanied by a decrease of DAT binding in a more restricted part of the posterior putamen. The current data do not permit us to posit separate causes for the local decrease but general increase of DAT binding in the striatum. Complementary approaches would be required to test whether, for example, the local decrease is a sign of moderate local fiber loss, and if the substantial increase is a compensatory mechanism in the rest of the striatum. We additionally showed that the early response to dopaminergic lesion in the premotor phase is significantly lateralized: the increase and the decrease of [ 11 C]PE2I-BP ND were more significant in the left anterior and left posterior putamen respectively. Behaviorally, we did not observe a lateralization of the onset of motor deficits with our clinical rating scale. Most probably, more precise evaluation is needed in order to make the link during this premotor phase (Picillo et al., 2013) . However, we identified a contralateral effect on cognitive performance deterioration. Even if no motor deficit were observed (i.e. clinical motor score null), the decrease of DAT binding in the left posterior putamen might have had an influence on motor control which would add to the increase of DAT binding in the caudate, ventral striatum and anterior putamen and its probable consequences on cognitive functioning. This is coherent with studies describing how reduced or excessive prefrontal DA can equally or differentially affect diverse cognitive functions (Cools, 2006; Cools et al., 2001; Cools and d'Esposito, 2011; Floresco, 2013) . We can reasonably argue that the emergence of a specific variety of premotor cognitive deficits might well correlate with a dopaminergic hypertonia in the caudate, ventral striatum and anterior putamen (Leviel, 2011) . Under the assumption that the [ 11 C]PE2I-BP ND decrease reflects an initial nigrostriatal lesion, this would lead to an increase in DA synthesis and release of remaining DA terminals (Zigmond et al., 2002) . This hypertonic DA state could have a direct role in deteriorated cognitive performance (Cools, 2011; Cools et al., 2003) . However, it can also be argued that the hypertonic DA state induces a compensatory DAT overexpression (Jakowec et al., 2004) at the levels of the remaining DA terminals which could lead to increased impulsivity (Costa et al., 2013) . Further research is required in order to identify whether the deteriorated cognitive performances can be imputed to the large DAT binding increase in the caudate, ventral striatum and anterior putamen or to the more restricted DAT binding decrease in the posterior putamen that we report here on a restricted number of cases.
The asymmetrical manifestation of motor symptoms in PD patients is well recognized and used as a hallmark of Parkinson's disease (Marek et al., 1996) , and a recent SPECT study in humans PD patients showed a lateralization of DAT availability in the posterior putamen Scherfler et al., 2012) . However, this is to our knowledge the first time the latter is demonstrated in the systemic MPTP-model of Parkinson's disease (Blesa et al., 2011) . We provide evidence that this lateralization in the premotor phase might to a large extent depend on the interhemispheric difference present in control scans, as the side with the highest labeling was the most affected following MPTP injections. This is coherent with the view that DA terminals presenting more DAT show increased sensitivity to subsequent intoxication (Bannon, 2005) . This needs further confirmation and if this is the case longitudinal monitoring of human patient populations presenting identified risks for the development of PD might be envisioned (Mossa et al., 2012; Ravina et al., 2012; Ziebell et al., 2012) .
We speculate that the initial DA cell death produced by MPTP causes externalization of the DAT sites responsible for DA release induced by the local enhancement of the glutamate metabolism acting on glutamate receptors located on the striatal DA terminals (Johnson and Jeng, 1991) . Importantly, a recent study confirmed the potentially harmful role of glutamate (Masilamoni et al., 2011) , showing that glutamate receptor antagonist has significant protective effects on midbrain DA neurons. This study also reported a transient striatal 18 F-FECNT increase but, in this case, the increase in measured DAT binding might possibly be more related to compensatory sprouting given longer time delays (Song and Haber, 2000) . We observed that similar increases of striatal DAT binding can be greatly prolonged over months with extended low-frequency/low-dose protocols (Unpublished results). As a consequence, this very early increase in the striatal [ 11 C]PE2I-BP ND was detectable before the occurrence of significant motor symptoms. Further investigations are needed in order to confirm the duration of this early DAT compensation on a longer timescale following MPTP-injections cessation and to delineate a therapeutic index. Such studies will give a better indication of the relevance of the present acute findings to the neurodegenerative processes occurring in PD over very extended periods.
Beyond the early MPTP condition and, in order to verify the expected reduction of DAT binding after prolonged MPTP intoxication, [ 11 C]PE2I-BP ND was followed subsequent to i) spontaneous motor recovery and ii) long-term symptomatic parkinsonian state. Monkeys that spontaneously recovered from motor deficits presented greatly reduced striatal DAT binding, as recently shown in-vivo with other radiotracers (Blesa et al., 2010 (Blesa et al., , 2012 . While clinical score improves during this period, DAT binding as measured with [11C]PE2I-BP ND declines, thus demonstrating a clear dissociation between clinical scores and DAT binding. This supports theories of compensatory mechanisms harmful for DA cells. Specifically motor compensation may involve mechanisms which generate byproducts that are harmful for the delicate DA cells population (Bezard et al., 1997a (Bezard et al., , 1997b Dzahini et al., 2010; Leviel, 2011) . Furthermore, this calls for a better distinction between the premotor and recovered animals. While both groups are clinically below the motor symptomatic threshold and express non-motor cognitive symptoms, they have clearly different levels of DAT binding which implies the engagement of different compensatory systems: DAT compensation in premotor animals and, according to the literature, non-DAT compensation in recovered animals (Boulet et al., 2008; Larsen et al., 2011; Smith and Greene, 2012) . We argue that non-DAT compensatory mechanisms still rely on a minimal amount of DAT or nigrostriatal DA fibers because high clinical scores were correlated with considerably lowered levels of DAT only after the induction of a stable parkinsonian state. We show that the only striatal region that was significantly correlated to the degree of motor impairments was the ventral striatum. Low levels of DAT binding are coherent with a reduction of nigrostriatal DA terminals following repeated MPTP injections (Bannon, 2005; Donovan et al., 1999) . This could also be explained by a change in DAT trafficking dynamics between plasmalemme and endosome (Chen et al., 2010; Mortensen and Amara, 2003) . Otherwise, we cannot exclude the involvement of non-DAT compensatory mechanisms but using probably transporters from the same family e.g. serotonin et noradrenaline (Larsen et al., 2011; Moron et al., 2002; Smith and Greene, 2012) .
In the following, we review the possible adaptive processes involved in early and late phases of MPTP intoxication and in particular, concerning the observed 19-23% increase in [ 11 C]PE2I-BP ND in the early phase: i) a global increase of the number of DA terminals exceeding the pretreated state seems less likely than a small reduction in the nigral DA cell population and striatal DA innervation; possibly less than after partial lesions of the nigrostriatal DA pathway in animals (Dzahini et al., 2010) and certainly smaller than in the early phases of PD investigated in humans. Our observation of a localized decrease in measured DAT binding in a restricted region of the posterior putamen suggests that the lesion following three MPTP injections corresponds to a moderate insult of the nigrostriatal system. Even if moderate, the DA innervation can only be reduced and cannot explain the increased [ 11 C]PE2I-BP ND . Sprouting of the surviving nigrostriatal terminations has been reported for longer delays after MPTP-intoxication offset (Song and Haber, 2000; Stanic et al., 2003) . However, further investigations of the delay after last MPTP injection need to be done in order to confirm compensatory sprouting of DA fibers.
Reported delays of 4-5 weeks (Song and Haber, 2000) for DA sprouting make this phenomenon unlikely to contribute to the increase in external DAT sites we observed 3-5 days following last MPTP injection. ii) Following partial lesions in animals and during early phases of degeneration there is an activation of DA metabolism and a reduction of DA uptake (Bezard et al., 2000; Gerhardt et al., 1996; Stanic et al., 2003) . These observations are completed by recent findings of increased DA and glutamate release in the striatum of rats with restricted 6-OHDA lesion in the SN (Dentresangle et al., 2001; Dzahini et al., 2010) . Note MPTP reduces the ability of DAT to uptake DA through a competitive process. Thus, an increased affinity of the DAT external uptake sites is unlikely to be involved in the increased [ 11 C]PE2I-BP ND we report here. iii) the process by which DA is tonically released in the striatum is known to involve DAT (Jakowec et al., 2004; Leviel, 2011) and an enhancement of this process could increase the availability of external DAT-sites for [ 11 C]PE2I binding. This hypothesis could explain both the increased DA release observed after restricted lesion of the SN and substantiate the role of glutamate in this process. Glutamate transmission is clearly related to changes in DAT functions and to the DAT-dependent DA release in the striatum (Dentresangle et al., 2001; Dzahini et al., 2010) . Glutamate increase in the striatum might combine with DAT increase to constitute an initial compensatory activation of synthesis and release of DA (Chuhma et al., 2004; Hnasko et al., 2010) . However, glutamate increase has been shown to be a detrimental consequence of the nigrostriatal DA lesion (Dzahini et al., 2010; Masilamoni et al., 2011) . Further, the initial DAT increase might sensitize DA terminals to subsequent intoxication (Bannon, 2005; Jakowec et al., 2004) . The lateralization in CTR scans is coherent with this view as the initial DAT decrease was also lateralized and affected primarily the left putamen which was displaying more DAT binding than the other hemisphere in CTR scans. Together, these results argue in favor of idiopathic parkinsonism possibly resulting from repeated small insults to the DA system that are amplified over time due to intrinsic DA compensation (Braak et al., 2003; Broussolle and Thobois, 2002; Calne, 1992; Calne and Langston, 1983) . Recent reports suggest that acting on this early and potentially harmful adaptive process could provide protection from further neurodegeneration (Masilamoni et al., 2011) . iv) DAT belongs to the same class of solute carrier as serotonin, GABA and norepinephrine transporters (Amara and Kuhar, 1993) . Hence, DA cell death could lead to the recruitment of other neurotransmission systems thereby contributing to the increased number of striatal DAT sites. Such a scenario would be in accordance with the known shift of phenotype of striatal GABAergic neurons of macaque monkeys after MPTP intoxication (Tande et al., 2006) . However, the time required for such a phenomenon (tested 4-5 weeks after the last MPTP injection) and the required size of the lesion make this hypothesis relatively unlikely. v) Glial cells could also contribute to the observed phenomena. Glial cells express DAT and it is known that neurodegeneration in PD is associated with prominent neuroinflammation where glial cells play a crucial role (Annese et al., 2012; Cicchetti et al., 2002; Takagi et al., 2007; Vazquez-Claverie et al., 2009; Villalba and Smith, 2011) .
Concerning the late phase, following interruption of the MPTPtreatment, functional recovery has been characterized by increased TH protein-mRNA (in the ventral striatum and mecencephalon) and unchanged DAT protein-mRNA (in the striatum and ventral mecencephalon) (Rothblat et al., 2001 ). However, we identified higher in-vivo DAT values in the striatum of motor recovered compared to symptomatic cases, consistent with previous reports on post-mortem DAT levels (Blesa et al., 2012; Mounayar et al., 2007) . Various mechanisms could be involved in this process and might be more related to the late phase of premotor or preclinical Parkinsonism. The extent of DA neuron loss in PD correlates with levels of DAT expression in specific brain regions (Bannon, 2005) . Hence it is believed that regions of low DA innervation (e.g. the ventral striatum) become critically involved in late compensatory mechanisms by constituting the surviving pool of DA neurons upon which non-DA compensation relies to be efficient. Sprouting of dopaminergic and/or serotoninergic fibers has also been reported (Boulet et al., 2008) following MPTP intoxication; although the amplitude of these effects appears too limited to entirely explain the near complete functional recovery observed in the present study. Moreover, a recent study favors the role of preserved DA terminals rather than the serotoninergic system in spontaneous recovery (Neumane et al., 2012) . Nonetheless, altered cortical serotonin levels could have contributed to changes in behavioral performance for the task used (Walker et al., 2006) . Further investigations are needed to determine whether the serotoninergic system is implied earlier than previously reported (Boulet et al., 2008; Neumane et al., 2012) and could have also contributed to behavioral changes observed during the pre-motor stage. Lastly, increased dopa-decarboxylase activity at DA terminals has been shown to play a compensatory role in nigrostriatal denervation (Brooks et al., 2003) and to explain why PET-scans using [
18 F] DOPA are less sensitive than DAT-scans to confirm DA denervation (Ribeiro et al., 2002) . Further research is needed to focus on this period (Vezoli et al., 2011) , as the processes involved are most probably mirroring those at play during late compensation in PD. Subcortical systems are likely to be implicated in the compensatory processes (Pifl et al., 2013) ; however, alterations of motor control remain well correlated to the severity of the degenerative process of the nigrostriatal pathway.
Conclusions
This study shows that DAT is differentially regulated after partial lesion and according to the level of DA neuron insult (Afonso-Oramas et al., 2010) . It can be concluded that the very early consequence of a mild MPTP intoxication and the associated nigrostriatal denervation induces the 19-23% increase of the [ 11 C]PE2I-BP ND on the DA terminals of striatal structures we observed in the macaque monkey. This is likely due to an increase of the number of DAT sites known to cause the local DA overflow following mild nigrostriatal denervation. This could allow transient regulation of DA homeostasis at the onset of the MPTP intoxication in monkeys and possibly during preclinical phases of Parkinson's disease. Further confirmation of this phenomenon has potential clinical applications in the early detection of the ongoing DA lesion and optimizing treatment of the disease. This very early adaptive mechanism is probably triggered at the level of the DA terminals, and could be harmful in the long-term due to interactions with glutamate transmission. These mechanisms could both persist but differ from those at play during behavioral recovery i.e. long-term compensation. Our results confirm that compensatory mechanisms can lead to normal motor behavior in MPTP-monkeys, despite a reduction of around 70% of the striatal [ 11 C]PE2I-BP ND . However, pushing this value to more than 80% reduction compared to control induces stable parkinsonian symptoms that no longer permit spontaneous recovery. This is in agreement with a large body of evidence suggesting that i) compensatory processes involve multiple systems but nevertheless invariably engages the DA pathway, and that ii) heterologous mechanisms are efficient provided about 20% of nigrostriatal projections remain functional. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
